medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2012, Number 2

<< Back Next >>

Rev Invest Clin 2012; 64 (2)

Major neurotransmitters involved in the regulation of sleep-wake cycle

Franco-Pérez J, Ballesteros-Zebadúa P, Custodio V, Paz C

Language: Spanish
References: 82
Page: 182-191
PDF size: 225.86 Kb.


ABSTRACT

Neuronal activity in the central nervous system undergoes a variety of electrophysiological changes along the sleep-wake cycle. These changes are modulated by a complex interaction between different neurochemical systems located throughout the brain. Within brainstem and hypothalamus there are a number of neuronal populations that promote wakefulness through the action of different neurotransmitters like noradrenaline, serotonin, histamine and orexin. These systems act together in the generation and maintenance of wakefulness, however although each one contributes in a unique way no neurotransmitter seems to be absolutely necessary because wakefulness is not completely inhibited in the absence of any of them. On the other hand, neurons located in the hypothalamus and brainstem are involved in initiating and maintaining sleep. These neurons contain neurotransmitters such as acetylcholine and GABA and have projections to nuclei involved in wakefulness regulation. Recently, models have been proposed suggesting that sleep is modulated by flip-flop switches which are characterized by neuronal circuits with different neurotransmitters and that interacting to regulate the initiation and maintenance of the different stages of sleep wake cycle. This review is based on pharmacological, electrophysiological and neurochemical studies with the aim of analyze the major neurotransmitters and the cerebral regions involved in the regulation of wakefulness and different states of sleep.


REFERENCES

  1. Aserinsky E, Kleitman N. Regularly occurring periods of eye motility and concomitant phenomena during sleep. Science 1953; 118: 273-4.

  2. García-García F, Acosta-Peña E, Venebra-Muñoz A, Murillo-Rodríguez E. Sleep-inducing factors. CNS Neurol Disord Drug Targets 2009; 8: 235-44.

  3. Lee SB, Beak SK, Park SH, Waterhouse BD, Lee HS. Collateral projection from the locus coeruleus to whisker-related sensory and motor brain regions of the rat. J Comp Neurol 2009; 514: 387-402.

  4. Sharma Y, Xu T, Graf WM, Fobbs A, Sherwood CC, Hof PR, et al. Comparative anatomy of the locus coeruleus in humans and nonhuman primates. J Comp Neurol 2010; 518: 963-71.

  5. Aston-Jones G, Bloom F. Activity of norepinephrine-containinglocus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle. J Neurosci 1981; 1: 876-86.

  6. Takahashi K, Kayama Y, Lin JS, Sakai K. Locus coeruleus neuronal activity during the sleep-waking cycle in mice. Neuroscience 2010; 169: 1115-26.

  7. Berridge CW, Stellick R, Schmeichel B. Wake-promoting actions of medial basal forebrain beta2 receptor stimulation. Behav Neurosci 2005; 119: 743-51.

  8. Berridge CW. Noradrenergic modulation of arousal. Brain Res Rev 2008; 58: 1-17.

  9. Berridge CW, España R. Synergistic sedative effects of noradrenergic alpha (1) and beta-receptor blockade on forebrain electroencephalographic and behavioral indices. Neuroscience 2000; 99: 495-505.

  10. Pal D, Mallick BN. Role of noradrenergic and GABA-ergic inputs in pedunculopontine tegmentum for regulation of rapid eye movement sleep in rats. Neuropharmacology 2006; 51: 1-11.

  11. Kumar R. Approved and investigational uses of modafinil: an evidence- based review. Drugs 2008; 68: 1803-39.

  12. Jouvet M. Biogenic amines and the states of sleep. Science 1969; 163: 32-41.

  13. Urbain N, Creamer K, Debonnel G. Electrophysiological diversity of the dorsal raphe cells across the sleep-wake cycle of the rat. J Physiol 2006; 573: 679-95.

  14. Monti JM. The role of dorsal raphe nucleus serotonergic and nonserotonergic neurons, and of their receptors, in regulating waking and rapid eye movement (REM) sleep. Sleep Med Rev 2010; 14: 319-27.

  15. Dzoljic M, Ukponmwan O, Saxena P. 5-HT1-like receptor agonists enhance wakefulness. Neuropharmacology 1992; 31: 623-33.

  16. Tejada S, Rial RV, Gamundí A, Esteban S. Effects of serotonergic drugs on locomotor activity and vigilance states in ring doves. Behav Brain Res 2011; 216: 238-46.

  17. Monti JM, Jantos H, Lagos P. Activation of serotonin 5-HT(1B) receptor in the dorsal raphe nucleus affects REM sleep in the rat. Behav Brain Res 2010; 206: 8-16.

  18. Monti JM, Leopoldo M, Jantos H. The serotonin 5-HT7 receptor agonist LP-44 microinjected into the dorsal raphe nucleus suppresses REM sleep in the rat. Behav Brain Res 2008; 191: 184-9.

  19. Monti JM, Jantos H. Activation of the serotonin 5-HT3 receptor in the dorsal raphe nucleus suppresses REM sleep in the rat. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 940-7.

  20. Kantor S, Jakus S, Bodizs R, Halasz P, Bagdy G. Acute and longterm effects of the 5-HT2 receptor antagonist ritanserin on EEG power spectra, motor activity and sleep: changes at the light-dark phase shift. Brain Res 2002; 943: 105-11.

  21. Morairty SR, Hedley L, Flores J, Martin R, Kilduff TS. Selective 5HT2A and 5HT6 receptor antagonists promote sleep in rats. Sleep 2008; 31: 34-44.

  22. Descamps A, Rousset C, Millan MJ, Spedding M, Delagrange P, Cespuglio R. Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture. Psychopharmacology 2009; 205: 93-106.

  23. Boothman L, Raley J, Denk F, Hirani E, Sharp T. In vivo evidence that 5-HT(2C) receptors inhibit 5-HT neuronal activity via a GABAergic mechanism. Br J Pharmacol 2006; 149: 861-9.

  24. Liu R, van den Pol A, Aghajanian G. Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions. J Neurosci 2002; 22: 9453-64.

  25. Steriade M, Datta S, Pare D, Oakson G, Curro R. Neuronal activities in brain-stem cholinergic nuclei related to tonic activation processes in thalamocortical systems. J Neurosci 1990; 10: 2541-59.

  26. Hassani OK, Lee MG, Henny P, Jones BE. Discharge profiles of identified GABAergic in comparison to cholinergic and putative glutamatergic basal forebrain neurons across the sleep-wake cycle. J Neurosci 2009; 29: 11828-40.

  27. Marrosu F, Portas C, Mascia M, Casu M, Fa M, Giagheddu M, et al. Microdialysis measurement of cortical and hippocampal acetylcholine release during sleep-wake cycle in freely moving cats. Brain Res 1995; 671: 329-32.

  28. Vazquez J, Baghdoyan HA. Basal forebrain acetylcholine release during REM sleep is significantly greater than during waking. Am J Physiol Regul Integr Comp Physiol 2001; 280: R598-R601.

  29. Ishida T, Kamei C. Characteristic effects of anti-dementia drugs on rat sleep patterns. J Pharmacol Sci 2009; 109: 449-55.

  30. Coleman C, Lydic R, Baghdoyan H. M2 muscarinic receptors in pontine reticular formation of C57BL/6J mouse contribute to rapid eye movement sleep generation. Neuroscience 2004; 126: 821-30.

  31. Marks G, Birabil C. Carbachol induction of REM sleep in the rat is more effective at lights-out than lights-on. Brain Res 2007; 1142: 127-34.

  32. Fenik VB, Kubin L. Differential localization of carbachol- and bicuculline- sensitive pontine sites for eliciting REM sleep-like effects in anesthetized rats. J Sleep Res 2008; 18: 99-112.

  33. Velazquez-Moctezuma J, Shalauta MD, Gillin JC, Shiromani PJ. Microinjections of nicotine in the medial pontine reticular formation elicits REM sleep. Neurosci Lett 1990; 115: 265-8.

  34. Vázquez-Palacios G, Hernández-González M, Guevara-Pérez MA, Bonilla-Jaime H. Nicotine and fluoxetine induce arousing effects on sleep-wake cycle in antidepressive doses: a possible mechanism of antidepressant-like effects of nicotine. Pharmacol Biochem Behav 2010; 94: 503-9.

  35. Fuller PM, Saper CB, Lu J. The pontine REM switch: past and present. J Physiol 2007; 584: 735-41.

  36. Vetrivelan R, Fuller PM, Tong Q, Lu J. Medullary circuitry regulating rapid eye movement sleep and motor atonia. J Neurosci 2009; 29: 9361-9.

  37. Szymusiak R, Alam N, Steininger TL, McGinty D. Sleep-waking discharge patterns of ventrolateral preoptic/anterior hypothalamic neurons in rats. Brain Res 1998; 803: 178-88.

  38. Suntsova N, Szymusiak R, Alam MN, Guzman-Marin R, McGinty D. Sleep-waking discharge patterns of median preoptic nucleus neurons in rats. J Physiol 2002; 543: 665–77.

  39. Suntsova N, Guzman-Marin R, Kumar S, Alam MN, Szymusiak R, McGinty D. The median preoptic nucleus reciprocally modulates activity of arousal-related and sleep-related neurons in the perifornical lateral hypothalamus. J Neurosci 2007; 27: 1616-30.

  40. Szymusiak R, McGinty D. Hypothalamic regulation of sleep and arousal. Ann N Y Acad Sci 2008; 1129: 275-86.

  41. Hirase M, Ishida T, Kamei C. Rebound insomnia induced by abrupt withdrawal of hypnotics in sleep-disturbed rats. Eur J Pharmacol 2008; 597: 46-50.

  42. Passarella S, Doung MT. Diagnosis and treatment of insomnia. Am J Health Syst Pharm 2008; 65: 927-34.

  43. Xi M, Chase MH. Effects of eszopiclone and zolpidem on sleep and waking states in the adult guinea pig. Sleep 2008; 31: 1043- 51.

  44. Nutt DJ, Stahl SM. Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol 2010; 24: 1601-12.

  45. Lancel M, Grönlein T, Faulhaber J. Role of GABAA receptors in sleep regulation. Differential effects of muscimol and midazolam on sleep in rats. Neuropsychopharmacology 1996; 15: 63-74.

  46. Alexandre C, Dordal A, Aixendri R, Guzman A, Hamon M, Adrien J. Sleep-stabilizing effects of E-6199, compared to zopiclone, zolpidem and THIP in mice. Sleep 2008; 31: 259-70.

  47. Thakkar MM, Winston S, McCarley RW. Effect of microdialysis perfusion of 4,5,6,7-tetrahydroisoxazolo-[5,4-c]pyridine-3-ol in the perifornical hypothalamus on sleep-wakefulness: role of delta- subunit containing extrasynaptic GABAA receptors. Neuroscience 2008; 153: 551-5.

  48. Deschaux O, Froestl W, Gottesmann C. Influence of a GABA(B) and GABA(C) receptor antagonist on sleep-waking cycle in the rat. Eur J Pharmacol 2006; 535: 177-81.

  49. Watanabe T, Taguchi Y, Shiosaka S, Tanaka J, Kubota H, Terano Y, et al. Distribution of histaminergic system in the central nervous system of rats: a fluorescent immunohistochemical analysis with histidine decarboxylase as a marker. Brain Res 1984; 295: 13-25.

  50. Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. Physiol Rev 2008; 88: 1183-241.

  51. Takahashi K, Lin JS, Sakai K. Neuronal activity of histaminergic tuberomammillary neurons during wake-sleep states in the mouse. J Neurosci 2006; 26: 10292-8.

  52. Sakai K, Takahashi K, Anaclet C, Lin JS. Sleep-waking discharge of ventral tuberomammillary neurons in wild-type and histidine decarboxylase knock-out mice. Front Behav Neurosci 2010; 4: 53.

  53. Monti J, Pellejero T, Jantos H. Effects of H1- and H2-histamine receptor agonists and antagonists on sleep and wakefulness in the rat. J Neural Transm 1986; 66: 1-11.

  54. Ramesh V, Thakkar M, Strecker R, Basheer R, McCarley R. Wakefulness-inducing effects of histamine in the basal forebrain of freely moving rats. Behav Brain Res 2004; 152: 271-8.

  55. Tokunaga S, Takeda Y, Shinomiya K, Hirase M, Kamei C. Effects of Some H1-Antagonists on the Sleep-Wake Cycle in Sleep-Disturbed Rats. J Pharmacol Sci 2007; 103: 201-6.

  56. Tokunaga S, Tsutsui R, Obara Y, Ishida T, Kamei C. Effects of histamine H1-antagonists on sleep-awake state in rats placed on a grid suspended over water or on sawdust. Biol Pharm Bull 2009; 32: 51-4.

  57. Lin JS, Sergeeva OA, Haas HL. Histamine H3 receptors and sleep-wake regulation. J Pharmacol Exp Ther 2011; 336: 17-23.

  58. Parmentier R, Anaclet C, Guhennec C, Brousseau E, Bricout D, Giboulot T, et al. The brain H3-receptor as a novel therapeutic target for vigilance and sleep–wake disorders. Biochem Pharmacol 2007; 73: 1157-71.

  59. De Lecea L, Kilduff T, Peyron C, Gao X, Foye P, Danielson P. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. PNAS 1998; 95: 322-7.

  60. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli R, Tanaka H, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998; 92: 573-85.

  61. Stoyanova I, Rutten WL, le Feber J. Orexin-A and orexin-B during the postnatal development of the rat brain. Cell Mol Neurobiol 2010; 30: 81-9.

  62. Ohno K, Sakurai T. Orexin neuronal circuitry: role in the regulation of sleep and wakefulness. Front Neuroendocrinol 2008; 29: 70-87.

  63. Lee M, Hassani O, Jones B. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci 2005; 25: 6716-20.

  64. Takahashi K, Lin JS, Sakai K. Neuronal activity of orexin and non-orexin waking-active neurons during wake-sleep states in the mouse. Neuroscience 2008; 153: 860-70.

  65. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999; 98: 365-76.

  66. Mishima K, Fujiki N, Yoshida Y, Sakurai T, Honda M, Mignot E, et al. Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy. Sleep 2008; 31: 1119-26.

  67. Thannickal T, Moore R, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000; 27: 469-74.

  68. Thannickal T, Nienhuis R, Siegel J. Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. Sleep 2009; 32: 993-8.

  69. Hagan J, Leslie R, Patel S, Evans M, Wattam T, Holmes S, et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. PNAS 1999; 96: 10911-6.

  70. Akanmu M, Honda K. Selective stimulation of orexin receptor type 2 promotes wakefulness in freely behaving rats. Brain Res 2005; 1048: 135-45.

  71. Brisbare-Roch C, Dingemanse J, Koberstein R, Hoever P, Aissaoui H, Flores S, et al. Promotion of sleep by targeting the orexin system in rats, dogs, and humans. Nat Med 2007; 13: 150-5.

  72. Porkka-Heiskanen T, Strecker R, McCarley R. Brain site-specificity of extracellular adenosine concentration changes during sleep deprivation and spontaneous sleep: an in vivo microdialysis study. Neuroscience 2000; 99: 507-17.

  73. McKenna J, Tartar J, Ward C, Thakkar M, Cordeira J, McCarley R, et al. Sleep fragmentation elevates behavioral, electrographic and neurochemical measures of sleepiness. Neuroscience 2007; 146: 1462-73.

  74. Schwierin B, Borbély A, Tobler I. Effects of N-cyclopentyladenosine and caffeine on sleep regulation in the rat. Eur J Pharmacol 1996; 300: 163-71.

  75. Okuro M, Fujiki N, Kotorii N, Ishimaru Y, Sokoloff P, Nishino S. Effects of paraxanthine and caffeine on sleep, locomotor activity, and body temperature in orexin/ataxin-3 transgenic narcoleptic mice. Sleep 2010; 33: 930-42.

  76. Thakkar M, Engemann S, Walsh K, Sahota P. Adenosine and the homeostatic control of sleep: effects of A1 receptor blockade in the perifornical lateral hypothalamus on sleep-wakefulness. Neuroscience 2008; 153: 875-80.

  77. Portas C, Thakkar M, Rainnie D, Greene R, McCarley R. Role of adenosine in behavioral state modulation: a microdialysis study in the freely moving cat. Neuroscience 1997; 79: 225-35.

  78. Oishi Y, Huang Z, Fredholm B, Urade Y, Hayaishi O. Adenosine in the tuberomammillary nucleus inhibits the histaminergic system via A1 receptors and promotes non-rapid eye movement sleep. PNAS 2008; 105: 19992-7.

  79. Franco-Pérez J, Paz C. Quinine, a selective gap junction blocker, decreases REM sleep in rats. Pharmacol Biochem Behav 2009; 94: 250-4.

  80. Saper C, Fuller P, Pedersen N, Lu J, Scammell T. Sleep state switching. Neuron 2010; 68: 1023-42.

  81. Hobson J, McCarley R, Wyzinsky P. Sleep cycle oscillation: reciprocal discharge by two brainstem neuronal groups. Science 1975; 189: 55-8.

  82. Lu J, Sherman D, Devor M, Saper C. A putative flip-flop switch for control on REM sleep. Nature 2006; 441: 589-94.




2020     |     www.medigraphic.com